Tarsons Products Limited has informed the Exchange about Transcript
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tarsons Products filed the transcript of its Q1 FY26 earnings call held on August 12, 2025. Consolidated revenue grew 8% YoY to INR 91 crores (standalone up 10% to INR 71 crores), driven by 12% growth in the domestic business. Standalone EBITDA margin improved to 31.2%, and cash PAT grew 38% to INR 21 crores, though reported PAT fell to INR 3.6 crores due to higher depreciation from the new Panchla facility. Management flagged the 50% US tariff as a major concern, noting it's hurting order momentum and making the international business outlook uncertain. The Panchla Phase 1 facility has begun commercial production, with Phase 2 expected in H2 FY26 and cell culture revenue starting in Q4.
Near-term sentiment is likely negative due to the US tariff headwind and weaker export growth (3% YoY), but new facility ramp-up, cell culture product line expansion, and guidance toward 40% EBITDA margins offer medium-term growth potential. Investors should watch for US trade deal clarity, Panchla capacity utilization, and debt reduction progress.